It seems AMBS strategy is anchored around Todos up-listing, and the delay is causing some pain. I think the funds raised through Reg A are mostly going to buy back debt/securities that are not converting at up-list. Since the Reg A filing will go through several iterations, it is a little disappointing that it was priced so low.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links